ROR is honored that it has been chosen to participate in a phase III clinical trial on a very promising cardiac PET agent from
This study is a phase 3, multicenter study for the assessment of ischemic heart disease in patients with suspected or known coronary artery disease.
In phase one and two studies at UCLA and Cedar Sinai Hospital, this new agent (F 18 Flurpiridaz) showed favorable results compared with the gold standard for evaluating ischemic heart disease non-invasively (nuclear medicine MPS MIBI). This study will evaluate the diagnostic efficacy (sensitivity and specificity) of Flurpiridaz F18 cardiac PET imaging compared to SPECT MPI imaging with Tc 99m MIBI.
These studies will be compared with interventional coronary angiography which will be the gold standard for comparing these agents. Patients will be paid for their time and expenses as part of this study up to $500 dollars and there will be no need to go through insurance if you qualify for this study.
To learn more about this study, you can contact our clinical nurse for this trial Jamie Plocky at
You are encouraged to speak to your doctor to find out if you would be a candidate for this trial or have your physician call Roy Gottlieb, D.O. FSCCT, Medical Director, Rolling Oaks Radiology at (805) 778-1513 for more information.
| About Us | Locations
| Services | News
| Billing & Insurance
| Careers | Contact